portfolio companies




Everest TherapeuticsBio


Nanoscale antibodies for therapeutic uses

Predict Immune

IBD Prognosis

Blood based prognosis device for IBD and other bowel diseases

Company introduction: Everest TherapeuticsBio was founded in 2019 and was also among the first batch of incubated enterprises in the Laguna Medical Incubator in Chengdu, China. The project focuses on developing nanoscale antibodies for therapeutic uses, and is currently led by Dr. Rajib Schubert from University of Zurich.

Product introduction: Peptide-Binding Reagent:

As a working binding agent (12kD and 6kD) for YFP, H2B and tubulin, the Peptide-Binding Reagent offers 3 distinct methods of detection. Each known epitope has only one target and can be read quantitatively. The product is easily scalable and also provides high yield rates.

Competitive Advantages:

  • Natural antibodies are considered mutable, inefficient and uncharacteristic. These antibodies are also bulky and somehow limit the tissue penetration. As reagents, they are fairly expensive, especially for high-concentration or high-volume reagent applications. Nanobodies, however, are single-domain antibodies and can be produced in E.coli, although they are still “designed” by animal immunity.
  • The price of nanobodies that are commercially available are comparable to the price of Abs, and their volume/concentration is alike. The dosing of nanobodies can also be adjusted accordingly for different conditions or expectations.


Company Profile: PredictImmune Ltd was founded in early 2017 and is a division of the University of Cambridge Medical School. As a new generation of molecular diagnostics companies, it provides a unique diagnostic method for the prognosis of immune-mediated diseases such as inflammatory bowel disease (IBD), lupus, and multiple sclerosis. The goal is to be the first company to provide predictive testing for immune-mediated diseases, which will promote personalized treatment for patients, thereby improving patient outcomes and health.

Product introduction: PredictSURE IBD:

PredictSURE IBD is the world’s first prognostic and CE-marked prognostic test for the treatment of inflammatory bowel disease IBD (Crohn’s disease and ulcerative colitis). PredictSURE IBD is based on an extensive study of CD8+ T cell gene expression profiles over the past 10 years. This whole blood biomarker test is an important step in the personalized treatment of IBD.

PredictSURE IBD is an easy-to-set biomarker test that combines sophisticated proprietary algorithms to tell patients about the likely course of disease and the severity of the disease. Medical institutions only need to collect a small blood sample from the patient (over 16 years old), and the patient can create an account to get online reports quickly. With PredictSURE IBD, healthcare organizations can control treatment options for Crohn’s disease and ulcerative colitis.

PredictSURE IBD was released in Europe in September 2019.

Team introduction: The Predict Immune team has a highly qualified and experienced core team that combines research experts from the University of Cambridge and business experts in the life sciences. After decades of deep cultivation, it can effectively implement medical research in clinical practice. . In terms of academic support, under the leadership of Ken Smith, Professor of Medicine and Head of the University of Cambridge, he has outstanding academic achievements in autoimmune diseases (especially inflammatory bowel disease, vasculitis and systemic lupus erythematosus), providing powerful products. Technical support and quality assurance; in terms of business support, experts with more than 25 years of corporate management experience in the global life sciences can judge the company’s business conduct and provide effective support for the company’s business operations.

Investment: Supported by the 4.7 million pound A round of equity financing provided by Parkwalk Opportunities Fund, Cambridge Enterprise and Wren Capital. In January 2018, it received a £4.3 million project investment from the Wellcome Trust. The company plans to raise more equity capital in 2019 to support the international commercialization of its products.